These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 12949556)

  • 1. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 2. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 3. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 4. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 5. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 6. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 7. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 8. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 9. IPO plans sour on both sides of the pond.
    Mitchell P
    Nat Biotechnol; 2004 Aug; 22(8):929-30. PubMed ID: 15286629
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 11. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 14. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 15. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 17. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechs await single European financial market.
    Louët S
    Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 20. Korean biotechs seize opportunity to list on public markets.
    Louët S
    Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.